CAMK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL546436	1.00	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL660382	0.49	4/20
SCHEMBL232042	1.00	3/20
SCHEMBL146734	0.67	3/20
SCHEMBL144651	0.67	3/20
SCHEMBL146677	0.67	3/20
SCHEMBL144378	0.66	3/20
SCHEMBL142020	0.65	3/20
SCHEMBL148704	0.62	3/20
SCHEMBL147730	0.61	3/20
SCHEMBL148478	0.61	3/20
SCHEMBL144118	0.61	3/20
SCHEMBL144615	0.61	3/20
SCHEMBL147715	0.61	3/20
SCHEMBL143818	0.61	3/20
SCHEMBL143827	0.59	3/20
SCHEMBL145924	0.59	3/20
SCHEMBL144183	0.58	3/20

Clinical trials — most relevant to CAMK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMS for Chronic Ulcers Treatment	PHASE4	RECRUITING
Multimodal Versus Opioid aNalgesia in carDiAc Surgery	PHASE4	COMPLETED
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?	PHASE2	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions	PHASE2	COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy	EARLY_PHASE1	RECRUITING
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia	nan	RECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Urine Concentration of S100B in Extremely Premature Infants	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CAMK1 binder may also engage these)

Protein	Name	Similarity
Q91YS8	—	1.000	Q91YS8 →
Q63450	—	1.000	Q63450 →
PNCK	Calcium/calmodulin-dependent protein kinase type 1B	0.994	landscape →
CAMK1D	Calcium/calmodulin-dependent protein kinase type 1D	0.994	landscape →
Q9QYK9	—	0.989	Q9QYK9 →
O70150	—	0.988	O70150 →
Q8BW96	—	0.988	Q8BW96 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.987	landscape →
Q9TXJ0	—	0.987	Q9TXJ0 →
W0LYS5	—	0.986	W0LYS5 →
A8X6H4	—	0.986	A8X6H4 →
Q6PFQ0	—	0.985	Q6PFQ0 →
Q54SJ5	—	0.983	Q54SJ5 →
Q869W6	—	0.982	Q869W6 →
Q6GLS4	—	0.981	Q6GLS4 →
Q9FMP5	—	0.981	Q9FMP5 →
Q5R4K3	—	0.981	Q5R4K3 →
DAPK2	Death-associated protein kinase 2	0.981	landscape →
Q8VDF3	—	0.980	Q8VDF3 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.980	landscape →
P13234	—	0.980	P13234 →
Q6U1I9	—	0.979	Q6U1I9 →
P18654	—	0.979	P18654 →
P18652	—	0.979	P18652 →
RPS6KA5	Ribosomal protein S6 kinase alpha-5	0.979	landscape →
RPS6KA2	Ribosomal protein S6 kinase alpha-2	0.979	landscape →
Q3E9C0	—	0.979	Q3E9C0 →
Q63531	—	0.979	Q63531 →
PRKCA	Protein kinase C alpha type	0.979	landscape →
Q9SZM3	—	0.979	Q9SZM3 →